Foster & Motley Inc. Lowers Position in Pfizer Inc. (NYSE:PFE)

Foster & Motley Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 1.8% in the 1st quarter, Holdings Channel reports. The fund owned 120,671 shares of the biopharmaceutical company’s stock after selling 2,262 shares during the quarter. Foster & Motley Inc.’s holdings in Pfizer were worth $3,058,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. William B. Walkup & Associates Inc. lifted its position in Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after acquiring an additional 454 shares during the period. Members Trust Co lifted its holdings in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 467 shares during the last quarter. Sutton Place Investors LLC boosted its position in shares of Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 472 shares in the last quarter. Bellevue Group AG grew its stake in shares of Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock worth $3,756,000 after buying an additional 485 shares during the last quarter. Finally, Gould Capital LLC increased its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.9%

Shares of Pfizer stock opened at $23.83 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $135.48 billion, a P/E ratio of 17.27, a P/E/G ratio of 0.88 and a beta of 0.58. The company has a fifty day moving average of $24.35 and a 200 day moving average of $24.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. The business’s revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.22%. Pfizer’s dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Redburn Atlantic reduced their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research note on Wednesday, April 30th. Wolfe Research increased their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.